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(ventricular asymmetry) that were thought to be 
unrelated to ZIKV infection.
Our findings suggest that prenatal ultrasonog-
raphy in ZIKV-infected pregnant women can 
detect ZIKV-associated morphologic changes in 
the fetus and thus may inform decision making 
among such women who may be considering 
pregnancy termination.5 Long-term functional 
outcome studies correlated to imaging findings 
are warranted.
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Clonal Hematopoiesis and Atherosclerosis
To the Editor: Jaiswal and colleagues (July 13 
issue)1 report that the presence of clonal hemato-
poiesis of indeterminate potential (CHIP) was as-
sociated with coronary heart disease. However, 
the use of the JAK2 V617F mutation as a marker 
of CHIP may be misleading, particularly when 
the mutant allele burden is high (up to 52% in 
this study). Unlike all the other mutations that 
were evaluated by the authors, JAK2 V617F is an 
initiating mutation that causes deregulated pro-
duction of red cells and platelets.2 It is a major 
criterion in the classification of the World Health 
Organization (WHO) for a diagnosis of myelo-
proliferative neoplasms, diseases that are often 
diagnosed after major thrombosis, including 
myocardial infarctions.3-5 Jaiswal and colleagues 
considered that leukocyte counts can be used to 
rule out myeloproliferative neoplasms, whereas 
hematocrit and platelet counts are much more 
relevant for this purpose, especially in polycythe-
mia vera and essential thrombocythemia. In the 
absence of full blood counts, one could speculate 
that many of the patients with a high JAK2 V617F 
allele burden are more likely to have undiag-
nosed myeloproliferative neoplasms than to be 
healthy CHIP carriers. Therefore, we suggest that 
the JAK2 V617F mutation should not be included 
in the definition of CHIP because of its specific 
involvement in the pathogenesis of myeloprolif-
erative neoplasms.
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Characteristic Value
Female sex — no. (%) 57 (55)
Age at MRI — days
Median (IQR) 61 (43–95)
Range 30–173
Gestational age at onset of maternal infection
Median (IQR) — wk 24 (12–32)
Range — no. (%)
>4 to 13 wk 31 (30)
>13 to 26 wk 25 (24)
>26 wk 47 (45)
Gestational age at birth — wk
Median (IQR) 39 (38–40)
Range 33–41
*  IQR denotes interquartile range, and MRI magnetic resonance imaging.
Table 1. Characteristics of the 103 Infants Who Underwent MRI.*
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To the Editor: Jaiswal et al. report the results of 
four case–control studies that confirm a near 
doubling in the risk of coronary heart disease in 
patients with CHIP,1 a finding that was first re-
ported in the Journal in 2014.2 The authors postu-
late that two mechanisms may be involved: the 
promotion of inflammatory responses, as sup-
ported in a study involving Tet2 knockout mice, 
and an increase in the number of myeloid cells, a 
finding that appears to be more relevant for pa-
tients with JAK2 mutations, which confer a much 
larger risk than the more common DNMT3A, TET2, 
and ASXL1 mutations, in which blood counts re-
main normal.
However, the authors do not provide data re-
lating to red-cell distribution width, which is the 
only blood-cell index that has been shown to 
have a significant association with CHIP2 and 
which has been associated with an unexplained 
increase in all-cause mortality in an aging popu-
lation.3,4 In understanding how CHIP promotes 
atherosclerosis, it is important to explore the 
causal relationship between clonal hematopoiesis 
and red-cell anisocytosis to determine whether 
these are independent or associated risk factors 
for cardiovascular disease.
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The authors reply: Cassinat et al. correctly state 
that patients with myeloproliferative neoplasms 
have an elevated risk of thrombosis, which several 
studies have concluded is related to the degree of 
leukocytosis but not thrombocytosis or erythro-
cytosis.1-3 In our previous study, five of the six 
patients with JAK2-mutated CHIP did not have 
any abnormalities in the complete blood count 
and thus would not have met the WHO criteria 
for either polycythemia vera or essential thrombo-
cythemia.4 In the current study, data regarding 
the complete blood count were available for pa-
tients from the Malmö Diet and Cancer prospec-
tive cohort study. Of the two patients with JAK2 
mutations in that cohort, one had no blood-count 
abnormalities and the other had mild thrombo-
cytosis (463,000 platelets per microliter). It is 
possible that clinically evident myeloproliferative 
neoplasms will be diagnosed in some, or even 
most, of these patients after several years. How-
ever, we believe it is premature to conclude that 
JAK2 V617F should not be included in the defini-
tion of CHIP on the basis of current information.
Phillips et al. suggest that increased red-cell 
anisocytosis may be associated with both CHIP 
and atherosclerotic cardiovascular disease, there-
by pointing to the causal biologic features that 
link these phenomena. Data on red-cell distribu-
tion width–standard deviation (RDW-SD) were 
available from the complete blood count in pa-
tients in the Malmö Diet and Cancer cohort. In 
this relatively small sample, CHIP was not sig-
nificantly associated with the RDW-SD. The pres-
ence of CHIP was associated with an increase in 
the RDW-SD of 1.85 fl (P = 0.32), after adjustment 
for age, sex, coronary heart disease status, type 2 
diabetes status, and smoking history. The inclu-
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sion of the RDW-SD in a Cox proportional-haz-
ards model for the development of coronary heart 
disease did not affect the risk estimate associ-
ated with CHIP (hazard ratio, 1.99; 95% confi-
dence interval, 1.26 to 3.13), after adjustment for 
RDW-SD, age, sex, hypertension, type 2 diabetes 
status, smoking history, and levels of high-den-
sity lipoprotein cholesterol and total cholesterol. 
On the basis of this limited sample, we found no 
evidence that red-cell anisocytosis, as indicated 
by an elevated RDW-SD, mediates the association 
between CHIP and atherosclerotic cardiovascular 
disease.
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Itraconazole or Amphotericin B for Talaromycosis
To the Editor: Le et al. (June 15 issue)1 report 
that amphotericin B was superior to itraconazole 
in the treatment of talaromycosis and that the 
rates of adverse events were higher with ampho-
tericin B use. However, some issues need to be 
discussed. The investigators did not report sever-
ity of illness or preexisting medical conditions. 
The treatment of talaromycosis depends on the 
severity of the infection, because itraconazole is 
recommended for milder forms of talaromycosis 
and amphotericin B or voriconazole for more se-
vere forms.2 The efficacy of treatment in both 
study groups can be misleading if, for instance, 
patients were not adequately treated or were 
overtreated on the basis of the severity of their 
infection. The presence of preexisting medical 
conditions could influence treatment outcomes, 
because patients with these conditions may be 
more susceptible to negative outcomes.
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To the Editor: Le et al. compared the efficacy of 
amphotericin B, administered intravenously, 
with that of itraconazole, administered orally, in 
the treatment of talaromycosis and found that 
amphotericin B was superior. The survival bene-
fit was thought to be associated with greater fun-
gicidal activity of amphotericin B, but the authors 
did not take into account the highly variable ab-
sorption kinetics of itraconazole capsules. Itra-
conazole is a weakly basic drug, and dissolution 
of the drug is pH-dependent; thus the drug re-
quires an acidic gastric environment for adequate 
absorption.1 Numerous studies have documented 
substantial variation in itraconazole exposure 
owing to the effect of food, interaction with co-
administered drugs, and adherence.2 Guidelines 
recommend assessment of the exposure to itra-
conazole through therapeutic drug monitoring 
when the drug is used for treatment of systemic 
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